Metabolic reprogramming in prostate cancer
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Although low risk localised prostate cancer has an excellent prognosis owing to effective treatments, such as surgery, radiation, cryosurgery and hormone therapy, metastatic prostate cancer remains incurable. Existing therapeutic regimens prolong life; however, they are beset by problems of resistance, resulting in poor outcomes. Treatment resistance arises primarily from tumour heterogeneity, altered genetic signatures and metabolic reprogramming, all of which enable the tumour to serially adapt to drugs during the course of treatment. In this review, we focus on alterations in the metabolism of prostate cancer, including genetic signatures and molecular pathways associated with metabolic reprogramming. Advances in our understanding of prostate cancer metabolism might help to explain many of the adaptive responses that are induced by therapy, which might, in turn, lead to the attainment of more durable therapeutic responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“As their name suggests, HIF proteins are induced in response to low oxygen concentrations, and increased levels have been linked to malignancy and poor prognosis in various cancers including prostate cancer.(32) As well as mediating an increase in the levels of glycolytic enzymes,(33) the major isoform, HIF1-α, induce…”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 2×
“Unlike normal cells, cancer cells rewire their cellular metabolism to promote growth and survival and thus have different nutritional requirements, and many different cancer types exhibit similar metabolic alterations.(1,2) The Warburg effect, for example, is a change in the metabolism of most cancer cells that enable…”
BackgroundThe Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088 · cited 1×
“Furthermore, tumour cells appear to turn on different programs of metabolic pathways to generate ATP, proteins, nucleotides and lipids for cellular proliferation compared with normal cells.(8) This review will explore important conceptual and technological advances in cancer metabolism with the goal of motivating the…”
BackgroundFundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 1×
“This alteration is, in part, orchestrated by the genetic changes that govern tumorigenesis,(2) such as the activation of oncogenes and/or the loss of tumour suppressor genes, and is further shaped by environmental factors, such as nutrient availability and oxygen concentration.(9) Tumours predominantly exhibit heterog…”
BackgroundMeta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577 · cited 2×
“For example, doses of 400 IU or more of vitamin E were seen to result in increased mortality in a study by Miller et al.121 However, findings from the Heart Outcomes Prevention Evaluation (HOPE) indicate no association between overall cancer risk and vitamin E intake.”
ResultThe mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Cited by
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts
Sychev, Z. E., Day, A., Bergom, H. E., Larson, G., Ali, A., Ludwig, M., Boytim, E., Coleman, I., Corey, E., Plymate, S. R., et al. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0976 · Cited by 13
Metadata
- Authors
- Ahmad, F., Cherukuri, M. K., & Choyke, P. L.
- Venue
- British Journal of Cancer
- Published
- 2021-07-14
- Volume
- 125
- Issue
- 9
- Pages
- 1185-1196
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W3180266641
- Cited by
- 212
- References
- 35
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic reprogramming in prostate cancer. https://app.cochat.ai/papers/10.1038/s41416-021-01435-5
- The paper
- Ahmad, F., Cherukuri, M. K., & Choyke, P. L. (2021). Metabolic reprogramming in prostate cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-021-01435-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.